Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN102 (modafinil + flecainide) for excessive daytime sleepiness in Parkinson's disease
2017-004475-31Phase 2Completed
- Sponsor
- Theranexus
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of THN102 in Parkinson's disease (PD) (3 arms), sponsored by Theranexus. Primary endpoint: Safety endpoints. Started Feb 2018; status: completed.
02
Drugs
THN102
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-004475-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004475-31.